TY - JOUR AU - Wilson, D AU - Seiffge, DJ AU - Traenka, C AU - Basir, G AU - Purrucker, JC AU - Rizos, T AU - Sobowale, OA AU - Sallinen, H AU - Yeh, S-J AU - Wu, TY AU - Ferrigno, M AU - Houben, R AU - Schreuder, FHBM AU - Perry, LA AU - Tanaka, J AU - Boulanger, M AU - Salman, RA-S AU - Jaeger, HR AU - Ambler, G AU - Shakeshaft, C AU - Yakushiji, Y AU - Choi, PMC AU - Staals, J AU - Cordonnier, C AU - Jeng, J-S AU - Veltkamp, R AU - Dowlatshahi, D AU - Engelter, ST AU - Parry-Jones, AR AU - Meretoja, A AU - Werring, DJ Y2 - 2021/02/04 Y1 - 2017/05/02 SN - 0028-3878 UR - http://hdl.handle.net/11343/259042 AB - OBJECTIVE: In an international collaborative multicenter pooled analysis, we compared mortality, functional outcome, intracerebral hemorrhage (ICH) volume, and hematoma expansion (HE) between non-vitamin K antagonist oral anticoagulation-related ICH (NOAC-ICH) and vitamin K antagonist-associated ICH (VKA-ICH). METHODS: We compared all-cause mortality within 90 days for NOAC-ICH and VKA-ICH using a Cox proportional hazards model adjusted for age; sex; baseline Glasgow Coma Scale score, ICH location, and log volume; intraventricular hemorrhage volume; and intracranial surgery. We addressed heterogeneity using a shared frailty term. Good functional outcome was defined as discharge modified Rankin Scale score ≤2 and investigated in multivariable logistic regression. ICH volume was measured by ABC/2 or a semiautomated planimetric method. HE was defined as an ICH volume increase >33% or >6 mL from baseline within 72 hours. RESULTS: We included 500 patients (97 NOAC-ICH and 403 VKA-ICH). Median baseline ICH volume was 14.4 mL (interquartile range [IQR] 3.6-38.4) for NOAC-ICH vs 10.6 mL (IQR 4.0-27.9) for VKA-ICH (p = 0.78). We did not find any difference between NOAC-ICH and VKA-ICH for all-cause mortality within 90 days (33% for NOAC-ICH vs 31% for VKA-ICH [p = 0.64]; adjusted Cox hazard ratio (for NOAC-ICH vs VKA-ICH) 0.93 [95% confidence interval (CI) 0.52-1.64] [p = 0.79]), the rate of HE (NOAC-ICH n = 29/48 [40%] vs VKA-ICH n = 93/140 [34%] [p = 0.45]), or functional outcome at hospital discharge (NOAC-ICH vs VKA-ICH odds ratio 0.47; 95% CI 0.18-1.19 [p = 0.11]). CONCLUSIONS: In our international collaborative multicenter pooled analysis, baseline ICH volume, hematoma expansion, 90-day mortality, and functional outcome were similar following NOAC-ICH and VKA-ICH. LA - English PB - LIPPINCOTT WILLIAMS & WILKINS T1 - Outcome of intracerebral hemorrhage associated with different oral anticoagulants DO - 10.1212/WNL.0000000000003886 IS - Neurology VL - 88 IS - 18 SP - 1693-1700 L1 - /bitstream/handle/11343/259042/PMC5409844.pdf?sequence=1&isAllowed=y ER -